Accepting risk in the acceleration of drug development for rare cancers

The Lancet Oncology

Volumn 16, Issue 4, 2015, Pages e190-e194

  Ashley, David ^a,b   Thomas, David ^c,d   Gore, Lia ^e,f   Carter, Rob ^a   Zalcberg, John R ^g   Otmar, Renée ^a   Savulescu, Julian ^h  

^a DEAKIN UNIVERSITY   (Australia)

^b Andrew Love Cancer Centre   (Australia)

^c GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^d GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^e CHILDREN S HOSPITAL COLORADO   (United States)

^f Department of Pediatrics   (United States)

^g MONASH UNIVERSITY   (Australia)

^h UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG DEVELOPMENT; GENETICS; HUMAN; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PATHOLOGY; RARE DISEASES; RESEARCH;

DRUG DISCOVERY; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; RARE DISEASES; RESEARCH;

EID: 84933523293     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)71153-2     Document Type: Note

References (13)

1. Decision no. 1295/1999/EC of the European Parliament and of the Council of 29 April 1999. Adopting a programme of community action on rare diseases within the framework for action in the field of public health (1999-2003) European Parliament and Council of the European Communities, (accessed Feb 5, 2015). http://eur-lex.europa.eu/legal-content/en/ALL/?uri=OJ:L:1999:155:TOC.
2. Developing products for rare disease and conditions US Department of Health and Human Services, Food and Drug AdministrationFood and Drug Administration, (accessed March 5, 2014). http://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/default.htm.
3. Greenlee RT, Goodman MT, Lynch CF, Platz CE, Havener LA, Howe HL The occurrence of rare cancers in U.S. adults, 1995-2004. Public Health Rep 2010, 125:28-43.
4. Improving rare cancer care in Europe: recommendations on stakeholder actions and public policies European Society for Medical Oncology, (accessed Nov 12, 2014). https://www.esmo.org/content/download/16802/296577/file/ESMO_Rare_Cancers_recommendations_2010.pdf.
5. Preview: rare cancers status report Rare Cancers Australia, (accessed March 5, 2014). http://www.rarecancers.org.au/page/16/preview-rare-cancers-status-report.
6. Gatta G, van der Zwan JM, Casali PG, et al. Rare cancers are not so rare: the rare cancer burden in Europe. Eur J Cancer 2011, 47:2493-2511. the RARECARE working group.
7. Rare Cancers Australia (accessed March 5, 2014). http://www.rarecancers.org.au/page/14/understanding-rare-cancers.
8. Pizzo PA Poplack DG. Principles and practice of pediatric oncology 2012, Lippincott, Williams & Wilkins, Philadelphia, PA.
9. Hagan K. The cost of cancer drugs. Age March 8, 2014.
10. 'Explore the Latest Progress on Medicines in Development' Pharmaceutical Research and Manufacturers of America, (accessed Oct 13, 2014). http://www.phrma.org/innovation/meds-in-development#sthash.1L3XypME.dpuf.
11. A national cancer clinical trials system for the 21st century: reinvigorating the NCI cooperative group program 2010, Institute of Medicine, The National Academies Press, Washington, DC.
12. Steensma DP, Kantarjian HM Impact of cancer research bureaucracy on innovation, costs, and patient care. J Clin Oncol 2014, 32:376-378.
13. Halpin L, Savulescu J, Talbot K, Turner M, Talman P Improving access to medicines: empowering patients in the quest to improve treatment for rare lethal diseases. J Med Ethics 2013, published online July 3. 10.1136/medethics-2013-101427.